Navigation Links
FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
Date:5/4/2010

tamine.  The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.

Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD.  Physicians should take a careful patient history, including family history, and physical exam to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease while taking Vyvanse should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by an increase in blood pressure or heart rate.

Additional information about Vyvanse and Full Prescribing Information, including the Medication Guide, are available at http://www.vyvanse.com.

INDICATION AND IMPORTANT SAFETY INFORMATION

Vyvanse is indicated for the treatment of ADHD. Efficacy based on two controlled trials in children aged 6 to 12 and two controlled trials in adults. Vyvanse is indicated as an integral part of a comprehensive treatment program that may include other measures (psychological, educational, social).

Amphetamines have a high potential for abuse; prolonged administration may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. See Full Prescribing Information for complete Boxed WARNING.

Vyvanse should not be taken by patients who have advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivi
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
2. FDA Approves New Device for Adults with Severe and Persistent Asthma
3. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
4. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
5. FDA Approves First Totally Implanted Hearing System
6. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
7. FDA Approves Name Change for Heartburn Drug Kapidex
8. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
9. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
10. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
11. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 ... convened in Boston on July ... in an effort to more fully exploit the potential ... applied to brain diseases. "As an established ... a responsibility to assume a leadership role - in ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... and Veracyte, Inc. (NASDAQ: VCYT ... a U.S. patient survey to advance understanding of ... including idiopathic pulmonary fibrosis (IPF). The Interstitial Lung ... steps and time required for patients to receive ...
(Date:8/27/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... cancer therapies, today announced that it will release its ... 30, 2015 on Friday, September 4, 2015. ... conference call and live webcast for investors, analysts and ...
Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3
... 6, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) announced ... National Breast Cancer Foundation (NBCF) by donating 5% of ... for the month of October to the NBCF. Solos ... across the Country through direct sales channels and social ...
... Va., Oct. 6, 2011 U.S. prescription sales through ... in 2010 — representing 87 percent of pharmaceutical sales ... Factbook . Now in its 83rd ... the Center for Healthcare Supply Chain Research, is a ...
Cached Medicine Technology:Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals 2Prescription Sales Through Healthcare Distributors Hit $268 Billion 2Prescription Sales Through Healthcare Distributors Hit $268 Billion 3
(Date:8/28/2015)... ... 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is the ... last three years, PREVENT ranks higher on the list than any other company in ...
(Date:8/28/2015)... ... 28, 2015 , ... The Wilson and Juanita Mann Health ... improving a patient’s quality of life through early diagnosis and treatment. The focus ... diabetes, HIV/AIDS, STDs, and others. A Women’s, Infants & Children (WIC) clinic also ...
(Date:8/27/2015)... ... August 28, 2015 , ... This new webinar educates providers about how can ... for the next visit, their authorizations are in check, and they are current with ... Barnes, COO for Genesis Chiropractic Software, growing a practice depends on patient experience and ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... cost to treat a patient with hemophilia is $175,000. Hemophilia is an inherited, ... and improving treatment. The RMHBDA exists to help raise funds for patients suffering ...
(Date:8/27/2015)... ... ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney announced today that ... on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. Syracuse Street, Denver, ... will present a two part seminar entitled, “How to Thrive as You Age & ...
Breaking Medicine News(10 mins):Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2Health News:Health Clinic Opening and Public Art Unveiling 2Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2
... discovered a potent and highly-debilitating toxin in the endangered ... now prompting investigations of other marine mammals in the ... marine algae common on coral reefs, and accumulates in ... human disease caused by ciguatoxin, affects thousands of people ...
... parental abuse as a child increases a person,s chances of ... research article in the current issue of the ... (Volume 66B, Number 3). An analysis of data ... early parental emotional abuse was associated with a higher number ...
... reports, lawsuits, congressional inquiries, claims and counterclaims, the question ... people lacks a definitive answer, according to a package ... edition of Chemical & Engineering News (C&EN), ACS,s weekly ... K. Ritter explains that BPA has been used in ...
... of nuclear stress tests, More women than men are ... studies ordered by primary care physicians ... Island and The Miriam hospitals suggests a possible gender ... tests, an imaging technique that measures blood flow to ...
... new generation of highly localized wireless networks that are ... from monitoring the functioning of implants, to tracking the ... But if this emerging technological area is to mature ... definition of its scope and potential, and a clearer ...
... ADDRESS SHORTAGE IN THE ICU , Intensive care ... worsen in the future. A recent study, conducted by ... Medical Center in New York, NY, studying 590 daytime ... non-physician providers can help address these staff shortages. ...
Cached Medicine News:Health News:Seniors abused during childhood face increased risk of sleep troubles 2Health News:Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals 2Health News:Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals 3Health News:The future of wireless body area networks is the focus of a June 19-20 workshop at WPI 2Health News:The future of wireless body area networks is the focus of a June 19-20 workshop at WPI 3Health News:Chest journal news briefs -- June 2011 issue 2
Very fine, blunt tip....
... The e.cam single-detector system ... with unrestricted access for gurneys ... features a clinically versatile open ... automatic body contouring for SPECT ...
Sharp diamond shaped double blade in stainless steel....
AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
Medicine Products: